Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Thurlings

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|August 23, 2006
[The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy]R M Thurlings, K Vos, D M Gerlag, et al.
Annals of the Rheumatic Diseases|October 30, 2007
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseR M Thurlings, K Vos, C A Wijbrandts, et al.
Gene Therapy|July 13, 2012
Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueF Mingozzi, Y Chen, S C Edmonson, et al.
Annals of the Rheumatic Diseases|July 15, 2009
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritisR M Thurlings, O Teng, K Vos, et al.
Arthritis and Rheumatism|January 1, 2008
Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose studyP P Tak, R M Thurlings, C Rossier, et al.
Annals of the Rheumatic Diseases|February 25, 2011
Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumabM M J Herenius, R M Thurlings, C A Wijbrandts, et al.
Annals of the Rheumatic Diseases|July 17, 2009
A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritisB J F van den Bemt, K Vos, A A den Broeder, et al.
Annals of the Rheumatic Diseases|August 4, 2010
Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activityT Groot Kormelink, J Tekstra, R M Thurlings, et al.
The Netherlands Journal of Medicine|March 9, 2016
A lethal case of the dapsone hypersensitivity syndrome involving the myocardiumR M Hoogeveen, T van der Bom, H H de Boer, et al.
The Journal of Investigative Dermatology|December 17, 2017
Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea"J S Mertens, E M G J de Jong, A Pandit, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nederlands Tijdschrift Voor Geneeskunde|August 23, 2006
[The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy]R M Thurlings, K Vos, D M Gerlag, et al.
Annals of the Rheumatic Diseases|October 30, 2007
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseR M Thurlings, K Vos, C A Wijbrandts, et al.
Gene Therapy|July 13, 2012
Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueF Mingozzi, Y Chen, S C Edmonson, et al.
Annals of the Rheumatic Diseases|July 15, 2009
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritisR M Thurlings, O Teng, K Vos, et al.
Arthritis and Rheumatism|January 1, 2008
Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose studyP P Tak, R M Thurlings, C Rossier, et al.
Annals of the Rheumatic Diseases|February 25, 2011
Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumabM M J Herenius, R M Thurlings, C A Wijbrandts, et al.
Annals of the Rheumatic Diseases|July 17, 2009
A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritisB J F van den Bemt, K Vos, A A den Broeder, et al.
Annals of the Rheumatic Diseases|August 4, 2010
Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activityT Groot Kormelink, J Tekstra, R M Thurlings, et al.
The Netherlands Journal of Medicine|March 9, 2016
A lethal case of the dapsone hypersensitivity syndrome involving the myocardiumR M Hoogeveen, T van der Bom, H H de Boer, et al.
The Journal of Investigative Dermatology|December 17, 2017
Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea"J S Mertens, E M G J de Jong, A Pandit, et al.
Pageof 2